Sign In
20 Jan 2010 07:00
ο»Ώ
PuriCore Pre-CloseΒ Trading UpdateΒ for Year Ended 31 December 2009
Increased Revenues of 28%Β and Significant Business Development
MALVERN, PENNSYLVANIA, AND STAFFORD, UK,Β 20 JanuaryΒ 2010Β -Β PuriCoreΒ (LSE: PURI), theΒ water-based clean technologyΒ company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, announcesΒ itsΒ pre-closeΒ trading update for the year ended 31 December 2009.Β Audited results for this period are expected to be announced in late April 2009.
Q4 and Full-YearΒ Financial ResultsΒ (unaudited)
UK EndoscopyΒ revenue increased 121% to $5.7 million (113%Β increaseΒ at constant currency)Β
UK EndoscopyΒ revenue, including Labcaire revenue as at August 2009,Β increased 19%Β to $16.4 million (41% increase at constant currency)
EarningsΒ estimatedΒ to be belowΒ Director'sΒ expectations, but not significantly so,Β due toΒ delays of expected Endoscopy sales into the next periodΒ and higher than anticipated field costsΒ
2009Β Operational Highlights
Launched Endoscopy on Demand and a new pass-through reprocessor
Received a new FDA 510(k) with expanded shelf-life claims
Greg Bosch, Chief Executive of PuriCore, said:
"2009 was a strong year forΒ PuriCoreΒ with record revenues in both core businesses despite the challenging economic climate. In our Food Safety business, we achieved record shipments with continued traction with the top national and regional retailers. Our Endoscopy business, including the acquisition of Labcaire, grew revenues more than 40% for the second year in a row and is now positioned as the top UK endoscopy disinfectant equipment and service provider. The integration of the Labcaire business is on schedule and proceeding smoothly. Looking ahead, we remain keenly focused on continuing to increase revenues, improve gross margins, and leverage our operating expenses in our core businesses whilst developing a third business franchise for our water-based clean technology."
Company Results
PuriCore achieved record results for the year with 28% top-line growth (at constant currency) and total revenues of $40.0 million. The Company expects to report a significant improvement in operating loss compared with prior year but a negative variance to Directors' expectations due toΒ delays of expected Endoscopy sales into the next period and higher than anticipated fieldΒ costs during the year, which the Company anticipates to be reduced going forward.Β The Company continued to reduce operating expenses throughout the year on its legacy business excluding the impact of Labcaire.Β PuriCore successfully completed fundraisings during the year including an equity Placing that raisedΒ Β£2 million (gross) to fund the acquisition of Labcaire Systems and the issuances of debt raising $2.7 million to fund leases in the Food Safety business.Β The Company's cash and cash equivalents at year end totalled $5.3 million.Β
Food Safety
PuriCore's Food Safety business in North America again achieved outstanding growth, driven in large part by the completion of installations of Sterilox Systems by the major nationals (now two of the top-five US retailers) in all of their stores. During the year,Β PuriCore completed the system-wide installation of Sterilox Food Safety Systems in all US and Canadian stores of Safeway, a top-five US supermarket retailer.Β The CompanyΒ alsoΒ won a contract and completed installationΒ inΒ the remaining Supervalu stores, another top-five US supermarket retailer.Β At year end, the CompanyΒ had increased its customer footprint from 30 to 53 retail brands including another top-10 US retailer and several leading regional chains.Β The Company installed approximately 1,250Β new SteriloxΒ Food Safety Systems across the US and Canada in 2009,Β bringing its total installed base to approximately 3,650Β SystemsΒ in the 53 retail brands. These brandsΒ represent approximately 20% of PuriCore's current targeted market of 29,000 North American stores, of which the Company has already installed 12%.Β As at 31 December 2009,Β PuriCore hadΒ sales opportunitiesΒ with other customers in negotiations, trials, or discussionsΒ representing an additionalΒ 40% of the market.Β The Company further estimates it could place aΒ second Sterilox system in approximately half of the North American stores for additional applications.Β
Endoscopy
With the acquisition of Labcaire Systems in August, PuriCore estimates its Endoscopy business is now the largest provider of endoscope disinfection equipment and services to UK NHS hospitals, private hospitals, and primary care networks. PuriCore Endoscopy had significant growth of 41% in 2009 on a constant-currency basis (including Labcaire Systems revenues as at August 2009) despite a clearly challenging economic environment. This growth performance was a function of increased unit placements as well as increased recurring revenue streams from lease contracts, service agreements, and related consumable products. During the year, PuriCore launched a new managed service, Endoscopy on Demand, and pass-through automated endoscopy reprocessor to meet market demand. At year end, PuriCore Endoscopy had placed reprocessing systems in approximately 350 NHS hospitals with endoscopy departments.Β
New Markets
In 2009,Β PuriCore transitioned exclusively from a clinical development programme toΒ Β commercialisation of the VasheΒ Wound Therapy platform. To dateΒ there have been more thanΒ 160,000 successful Vashe treatments, with totalΒ 2009 sales of $0.5Β millionΒ (inclusive of Dental revenues).Β The Company received a new FDA 510(k) clearance for Vashe Wound Therapy, which extends the shelf lifeΒ and enables wound care clinics greater flexibility in use of the therapy. In late 2009, a clinical study presented highlighted Vashe Wound Therapy as an effective and economical therapy for burn wounds.
2010Β Outlook
In 2010, the companyΒ anticipatesΒ cash flowΒ profitability inΒ PuriCore's Endoscopy business in the UK and continued significant progress in the Food Safety business in both the US and Canada.Β Throughout the year,Β PuriCoreΒ will continue to focus on growth in its two core businesses: North American Food Safety and UK Endoscopy, and further establish its Wound Care market presence.Β Consistent with past practice, the CompanyΒ will seek debt financing for leased systems and continue to review additionalΒ financingΒ forΒ businessΒ growth.Β Additionally, the Company will continue to seek further opportunities for its water-based clean technology through active business development. The Directors remain confident in the Company's prospects for 2010 and beyond.
Enquiries:Β
|
Ben Brewerton Susan Quigley Financial Dynamics +44 (0) 20 7831 3113 |
Greg Bosch, CEO Darren Weiss,Β CFO PuriCore +1 484 321 2700 |
About PuriCore
PuriCoreΒ plc (LSE: PURI) is aΒ water-based clean technologyΒ company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, wound care, and water treatment. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats ofΒ C.difficile,Β E.coli, HIV, Human and Animal Influenza (includingΒ H1N1 andΒ H5N1),Β Legionella, MRSA,Β M.tuberculosis, Norovirus, andΒ Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK.Β
To receive additional information on PuriCore, please visit our website atΒ www.puricore.com, which does not form part of this press release.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
All 2009Β financials are unaudited.
Follow the stocks
